In the tumor microenvironment, while TLR agonists can locally activate immunity, they are often accompanied by compensatory upregulation of immune checkpoints like PD-L1, limiting efficacy (Sistigu et al., 2014). This evidence concerns the gene CD274 and neoplasm.